Business Wire

MARY-KAY

2.11.2021 18:48:11 CET | Business Wire | Press release

Share
Mary Kay Inc. Supports Female Entrepreneur-Led Project to Improve Water Security in Monterrey in Partnership With The Nature Conservancy

Mary Kay Inc. is proud to announce the sponsorship of a project to improve water security in Monterrey in partnership with The Nature Conservancy. The project, led by a group of female entrepreneurs, focuses on restoring local species of trees in the surrounding areas of the city of Monterrey to help maintain ecosystem services, decrease the risk and impact of floods in the city, and restore the degraded forests in the region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102006106/en/

The City of Monterrey is currently home to four million people. Located in an area naturally prone to extreme hydrometeorological events such as hurricanes and flooding, the city often faces serious water supply challenges. Near the city is the Cumbres de Monterrey National Park, a protected natural reserve that accounts for about 60% of the water that comes to the city. The area also supports the control of heavy stormwater runoff which impacts people, local livestock, and urban infrastructure. To maintain environmental resiliency, vegetation cover needs to be restored and the production of native plants in nurseries must be ensured. While the National Commission of Protected Natural Areas of Mexico (CONANP) has established regulations requiring the use of native species for reforestation, forest nurseries in the region do not have the capacity to meet this demand. The area also offers very few opportunities for local farmers to develop self-sustaining economic activities.

“We are very happy to be able to count on this help that encourages us to continue working for the benefit of nature and to be able to generate resources that improve our local economy,” said Doña Angelica, leader of Mujeres Unidas Para La Conservación de Laguna de Sanchez, one of The Nature Conservancy’s partner organizations in Mexico. “With this help we will be able to reduce the production costs of plants that will be used in future reforestations.”

Mary Kay and The Nature Conservancy are supporting a group of female entrepreneurs in the Laguna Sanchez community who are leading a unique initiative to combat these challenges. This group of landowners is producing several native species of plants to be used for reforestation projects in the national park. The project will not only address the rising need for these species, but also improve livelihoods for their families and rural community members. Their forest nursery has the capacity to grow around 45,000 trees per year, including white pine (Pinus pseudostrobus ) and stone pine (Pinus cembroides ). These species, included in a scientific tool developed by The Nature Conservancy for ecological restoration in the area, are known for preventing erosion, promoting water infiltration, drought tolerance, and have the ability to regrow.

“Empowering women and preserving the Earth’s resources are two of the pillars of Mary Kay’s purpose,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “As an advocate for women’s leadership, we are very proud to see how these local leaders are steering the change in our community, playing a critical role in the preservation of our most valuable natural resource and nurturing a sustainable future for thousands of families in the region.”

To help tell the story of empowerment and natural conservation of Angelica and Mujeres Unidas Para La Conservación de Laguna de Sanchez , Mary Kay Inc. has produced a short film in partnership with The Nature Conservancy. Written, directed and produced by an all-female team, Forest of Hope is a journey to the frontlines of the battle to save our planet from the impending threats of climate change and destructive human behavior, where we see the difference a group of women conservationists can make. Watch the trailer of Forest of Hope here .

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more about Mary Kay at www.marykayglobal.com

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release

One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye